Latest Prasugrel Stories
Daiichi Sankyo Company and Eli Lilly and Company have confirmed that the FDA did not complete its review for the prasugrel new drug application by the Prescription Drug User Fee Act goal date of September 26, 2008.
TOKYO and INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, and Eli Lilly and Company confirmed today that the U.S.
MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs.
Eli Lilly and Company has announced encouraging results from a sub-group analysis of the Triton-TIMI 38 trial, which showed that patients who were diabetic and diagnosed with acute coronary syndromes were 40% less likely to suffer a heart attack if they were treated with prasugrel compared to clopidogrel.
MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were diabetic and diagnosed with acute coronary syndromes (ACS) were 40 percent less likely to suffer a heart attack if they were treated with prasugrel vs.
By Anonymous If Eli Lilly and Co. wins approval for its highly anticipated blood thinner, it could spark a bit of a family feud with Bristol- Myers Squibb Co., the maker of a competing drug. There are some signs it already is.
TOKYO and INDIANAPOLIS, Aug.
By Jeanine Kendle Plavix (clopidogrel) is a fairly well-known drug with considerable media coverage for cardiac conditions to prevent platelet (blood cell component) aggregation (sticking/clumping together).
Eli Lilly and Co. says the U.S. Food and Drug Administration has extended the review period for the experimental blood thinner prasugrel. The drug, which would be marketed under the name Effient, will be up for review by the FDA in September, Eli Lilly said Monday.
Daiichi Sankyo Company and Eli Lilly and Company have said that the FDA has extended the review period for the prasugrel new drug application based on supplemental information provided during the review period. This three-month extension allows the FDA time to complete its review.
- The act of sweetening by admixture of some saccharine substance.